Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-finding study of norUDCA in primary sclerosing cholangitis
NL-OMON39746Phase 2Active, not recruiting
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of norursodeoxycholic acid in Primary Sclerosing Cholangitis (PSC) (4 arms), sponsored by Dr. Falk Pharma GmbH. Primary endpoint: Mean relative change in serum alkaline phosphatase. Started Apr 2013; status: active, not recruiting.
02
Drugs
norursodeoxycholic acid
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on NL-OMON39746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39746.